Skip to main content

Table 2 Subgroup analysis of remission and response rate in week 0–12 in studies comparing pharmacogenomics testing guided and usual care group in MDD patients

From: Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT

 

Response

Remission

Study

/sample size

OR (95%CI)

I2

(%)

Pbetween

Study

/sample size

OR (95%CI)

I2

(%)

Pbetween

Study design

Single-center

2/120

2.13 (0.96, 4.73)

0

0.26

3/268

3.96 (2.32, 6.78)

50

< 0.01

Multi-center

7/4509

1.34 (1.04,1.77)

60

7/4022

1.62 (1.34, 1.95)

0

Sample size

< 200

4/549

1.66 (1.13, 2.45)

35

0.27

6/804

2.36 (1.37, 4.05)

57

0.07

≥ 200

5/4080

1.29 (0.97, 1.72)

62

4/3486

1.61 (1.31, 1.98)

0

Population

Caucasian

7/4458

1.31 (1.14, 1.50)

47

0.03

7/3971

1.59 (1.31, 1.92)

0

< 0.01

Asian

2/171

2.70 (1.42, 5.13)

0

2/171

2.27 (1.20, 4.28)

0

NA

-

-

-

 

1/107

-

-

 

Diagnostic criteria

HAM-D17

8/2555

1.57 (1.11, 2.23)

60

0.48

9/2535

1.95 (1.24, 3.07)

71

0.46

PHQ-9

2/3243

1.37 (1.17, 1.60)

0

2/3243

1.42 (1.16, 1.74)

0

Industry

funding

Fully

3/606

1.37 (0.62, 3.00)

81

0.70

3/290

4.89 (2.81, 8.52)

0

< 0.01

Partially

5/3952

1.37 (1.18, 1.59)

17

6/3929

1.57 (1.30, 1.90)

0

None

1/71

-

-

1/71

-

-

  1. MDD: major depressive disorder; OR, odds ratio; CI, Confidence interval; Pbetween, P-value between subgroup; NA, not available; HAM-D17, 17-item Hamilton Depression Rating Scale; PHQ-9, 9-item Patient Health Questionnaire; bold indicate significant difference